Liposomal NAD+ in 2026: what the research says

Liposomal NAD+ describes NAD+ enclosed in liposomes made from lipid bilayers. Nicotinamide adenine dinucleotide (NAD+) was tested in a laboratory liposomal preparation in cultured human cells and skin explants, rather than in people taking a commercial oral product. That study cannot establish an oral supplement’s clinical results or the effects of a prescribed injection.

If you are comparing a product with prescribed NAD+ injections, bring its complete ingredient information. This guide helps you identify which questions concern the molecule, which concern the formulation and which concern the evidence.

What ingredient is actually listed?

Start with the ingredient panel, even if the title prominently says NAD. Write down the complete name rather than relying on the abbreviation. If the product lists multiple ingredients, keep them all in the question you take to the clinician or pharmacist.

Ask whether the seller is naming the supplied ingredient or describing a pathway involving NAD. Those are different kinds of information. A product page can discuss the body’s use of a molecule without containing that molecule itself.

How do precursors differ?

NMN and NR are distinct NAD-related precursors, while NAD+ is the coenzyme itself. Their relationship in NAD metabolism does not make every preparation interchangeable. The source used for a product claim should identify the molecule actually studied.

The NMN-versus-NAD guide addresses that naming distinction in more detail. For a liposomal product, the first practical step remains the same: identify the full ingredient before evaluating a delivery description.

If a website uses different names in different places, ask which one applies to the product being supplied. Preserve the wording that confused you so the answer can address a specific discrepancy.

What does liposomal add to the name?

Liposomal describes the experimental formulation in the reviewed laboratory study. It does not change the need to identify the underlying ingredient and the route used. The study compared a particular liposomal NAD+ preparation with NAD+ alone in its experimental setting.

Ask what formulation the product uses and what evidence concerns that formulation. A general statement about liposomal technology should not be assumed to validate every product using the word. The connection between the actual label and the cited experiment should be made explicit.

Does a delivery description prove benefit?

It does not answer the clinical question by itself. Ask what result was measured and whether it is the result you mean. A comparison about a formulation can leave a question about a noticeable clinical effect unanswered.

Keep these distinctions visible in your notes:

• Ingredient: the specific molecule listed.
• Formulation: how the preparation is described.
• Route: how the product is intended to be administered.
• Research: what preparation the source actually tested.
• Claim: what result the page says you should expect.

These labels are a way to organize questions. They are not a certificate of product quality or suitability.

What did the laboratory work examine?

A laboratory study compared liposomal NAD+ with NAD+ alone in cultured human cells and skin explants, rather than testing an oral supplement or injection in patients.¹

The reviewed experiment included cultured vascular endothelial cells, epidermal keratinocytes and skin outside the body. Those models are not people swallowing a supplement or receiving a prescribed injection. The setting must remain part of the explanation.

Look for the experimental model when you read a summary. The phrase human cells can sound like a human clinical trial if the surrounding description leaves out the laboratory setting. Ask whether people were participants or whether the work used cells of human origin.

Can I apply the findings to my product?

The study does not establish human oral absorption of a commercial product, clinical effects of a home injection or performance of a passive patch. Its formulation and experimental application differ from those preparations.

Ask the seller or clinician to explain the evidence connection for the actual product. An answer can acknowledge an interesting laboratory finding while saying that a patient-facing question remains open. That is a more useful explanation than treating the product name as the missing connection.

The guide to NAD+ research and benefits explains broader evidence differences. Here, the narrow point is that an experimental liposomal preparation is not automatically the commercial preparation you are considering.

Do oral studies answer the question?

In a study of healthy middle-aged and older adults, oral supplementation with an NAD+ precursor (nicotinamide riboside) raised blood NAD+ levels and was well tolerated.²

The Martens trial used oral nicotinamide riboside, a precursor, rather than an oral liposomal NAD+ product. Its blood measurements and tolerability finding belong to that preparation. They cannot establish the result of every product with NAD in its title.

The oral precursor trial and the liposomal laboratory work are separate experiments. Putting the references beside each other does not create a human trial of an oral liposomal NAD+ preparation.

What if a page combines several references?

Ask which reference supports each specific claim. One source may explain a molecule and another may describe a different delivery system. If no source tests the complete preparation and result being advertised, that missing evidence should remain clear.

You can make the question concrete by naming the claim and the product. Ask whether the source used the same ingredient and administration route. If the answer concerns a different preparation, request a plain explanation of what can and cannot be concluded.

Do not assume that a longer reference list is automatically a closer evidence match. Relevance depends on what the studies actually tested, not just how many titles appear at the bottom of a page.

How can I compare an injection?

Compare the evidence questions rather than assuming one route wins. Identify the product on each side, the intended purpose and the source being used to support it. If the preparations differ, ask the clinician how that difference limits the comparison.

An uncertain claim about an oral product does not itself establish a reason to receive a prescription. Explain your interest in your own words and ask whether the proposed preparation is relevant to that concern. A format preference and an outcome expectation should be discussed separately.

Which information should I bring?

Bring the complete label, the product page that prompted your question and a list of what you already take. Explain whether you have used the product or are only considering it. Those details help avoid a conversation based on an assumed regimen.

Ask for clarification if the explanation changes between NAD+, NMN, NR and a blend. You should know which ingredient the answer concerns at each point. The goal is a product-specific discussion, rather than a broad promise about the entire NAD-related category.

What does a physician weigh?

Ask what the clinician considers known about the preparation, what remains uncertain and why it is being discussed in your evaluation. A clear explanation can remain useful even when the evidence does not provide a simple product ranking.

Compounded medications are prepared by a licensed pharmacy for an individual patient and are not FDA-approved. No approved label lists its uses or side effects, so the physician works from your history and clinical judgment, tells you what is known and what is uncertain, and sets how often you check in.

Any injectable can cause a reaction at the injection site or an allergic reaction, and NAD+ infusions are known for flushing and nausea when given quickly. Report anything unexpected to the physician the same day, and tell the physician about every medicine and supplement you take before anything is prescribed.

For severe allergic symptoms such as breathing difficulty or throat swelling, seek emergency care and call 911. Emergency care takes priority over a routine same-day report.

The infusion reference in that wording does not establish a reaction rate for an oral liposomal product or a home injection.

Treatment requires a prescription. A licensed clinician evaluates you by telehealth and decides whether any medication is appropriate. Booking does not guarantee a prescription.